About: Anti-infective immunoadhesins from plants

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Anti-infective immunoadhesins from plants Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Anti-infective immunoadhesins from plants
Creator	Maclean, James Belle, Archana Hayden, Frederick Roy, Chad Tran, Y Wycoff, Keith Yu, Lloyd
source	Medline; PMC
abstract	Immunoadhesins are recombinant proteins that combine the ligand-binding region of a receptor or adhesion molecule with immunoglobulin constant domains. All FDA-approved immunoadhesins are designed to modulate the interaction of a human receptor with its normal ligand, such as Etanercept (Enbrel(®)), which interferes with the binding of tumour necrosis factor (TNF) to the TNF-alpha receptor and is used to treat inflammatory diseases such as rheumatoid arthritis. Like antibodies, immunoadhesins have long circulating half-lives, are readily purified by affinity-based methods and have the avidity advantages conferred by bivalency. Immunoadhesins that incorporate normal cellular receptors for viruses or bacterial toxins hold great, but as yet unrealized, potential for treating infectious disease. As decoy receptors, immunoadhesins have potential advantages over pathogen-targeted monoclonal antibodies. Planet Biotechnology has specialized in developing anti-infective immunoadhesins using plant expression systems. An immunoadhesin incorporating the cellular receptor for anthrax toxin, CMG2, potently blocks toxin activity in vitro and protects animals against inhalational anthrax. An immunoadhesin based on the receptor for human rhinovirus, ICAM-1, potently blocks infection of human cells by one of the major causes of the common cold. An immunoadhesin targeting the MERS coronavirus is in an early stage of development. We describe here the unique challenges involved in designing and developing immunoadhesins targeting infectious diseases in the hope of inspiring further research into this promising class of drugs.
has issue date	2015-08-04(xsd:dateTime)
bibo:doi	10.1111/pbi.12441
bibo:pmid	26242703
has license	bronze-oa
sha1sum (hex)	2b030fac70adb320ab9da8a4d36a90e60614ced7
schema:url	https://doi.org/10.1111/pbi.12441
resource representing a document's title	Anti-infective immunoadhesins from plants
has PubMed Central identifier	PMC4749143
has PubMed identifier	26242703
schema:publication	Plant Biotechnology Journal
resource representing a document's body	covid:2b030fac70adb320ab9da8a4d36a90e60614ced7#body_text
is schema:about of	named entity 'combine' named entity 'Enbrel' named entity 'targeting' named entity 'COMMON COLD' named entity 'BLOCKS' named entity 'HALF' named entity 'DECOY' named entity 'VIRUSES' named entity 'GREAT' named entity 'UNIQUE' named entity 'EXPRESSION' named entity 'TARGETING' named entity 'USING' named entity 'IMMUNOGLOBULIN' named entity 'TREATING' named entity 'CMG2' named entity 'DEVELOPING' named entity 'ICAM-1' named entity 'MONOCLONAL ANTIBODIES' named entity 'HUMAN' named entity 'infectious disease' named entity 'potential' named entity 'TNF' named entity 'advantages' named entity 'common cold' named entity 'TNF-alpha' named entity 'developing' named entity 'targeting' named entity 'antibodies' named entity 'region' named entity 'Planet' named entity 'purified' named entity 'half-lives' named entity 'receptor' named entity 'CMG2' named entity 'ligand' named entity 'cellular receptors' named entity 'receptor' named entity 'plants' named entity 'monoclonal antibodies' named entity 'challenges involved' named entity 'binding region' named entity 'decoy receptors' named entity 'expression systems' named entity 'CMG2' named entity 'pathogen' named entity 'infection' named entity 'class of drugs' named entity 'MERS coronavirus' named entity 'rheumatoid arthritis' named entity 'tumour necrosis factor' named entity 'Enbrel' named entity 'monoclonal antibodies' named entity 'anion exchange chromatography' named entity 'goat' named entity 'antitoxin' named entity 'toxin' named entity 'LD 50' named entity 'Protein expression' named entity 'halflives' named entity 'mRNA' named entity 'infection' named entity 'HRV' named entity 'glycosylated' named entity 'CMG2' named entity 'immune response' named entity 'in-frame' named entity 'host cells' named entity 'Hantavirus infection' named entity 'Hui' named entity 'PTGS' named entity 'cell surface' named entity 'infectious disease' named entity 'ligand-binding' named entity 'FDA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software